ATE226444T1 - Verwendung von fgf-5 polypetiden zur vorbeugung des absterbens retinaler neuronen und behandlung okularer krankheiten - Google Patents

Verwendung von fgf-5 polypetiden zur vorbeugung des absterbens retinaler neuronen und behandlung okularer krankheiten

Info

Publication number: ATE226444T1
Authority: AT; Austria
Prior art keywords: retinal; retinopathies; fgf; cells; retinopathy
Prior art date: 1998-03-12

Application number

AT99912439T

Other languages

English (en)

Inventor

Ivar J Kljavin

Fleur Monique La

Original Assignee

Genentech Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-03-12

Filing date

1999-03-10

Publication date

2002-11-15

1999-01-29 Priority claimed from US09/240,952 external-priority patent/US6331523B1/en

1999-03-10 Application filed by Genentech Inc filed Critical Genentech Inc

2002-11-15 Application granted granted Critical

2002-11-15 Publication of ATE226444T1 publication Critical patent/ATE226444T1/de

Links

102100028073 Fibroblast growth factor 5 Human genes 0.000 title abstract 3
108090000380 Fibroblast growth factor 5 Proteins 0.000 title abstract 3
210000001116 retinal neuron Anatomy 0.000 title abstract 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
201000010099 disease Diseases 0.000 title 1
230000016273 neuron death Effects 0.000 title 1
206010038923 Retinopathy Diseases 0.000 abstract 7
201000007737 Retinal degeneration Diseases 0.000 abstract 3
210000004027 cell Anatomy 0.000 abstract 3
230000004258 retinal degeneration Effects 0.000 abstract 3
208000004142 Acute Retinal Necrosis Syndrome Diseases 0.000 abstract 2
206010011878 Deafness Diseases 0.000 abstract 2
230000010370 hearing loss Effects 0.000 abstract 2
231100000888 hearing loss Toxicity 0.000 abstract 2
208000016354 hearing loss disease Diseases 0.000 abstract 2
208000014674 injury Diseases 0.000 abstract 2
208000030507 AIDS Diseases 0.000 abstract 1
206010053227 AIDS retinopathy Diseases 0.000 abstract 1
206010059245 Angiopathy Diseases 0.000 abstract 1
208000031104 Arterial Occlusive disease Diseases 0.000 abstract 1
208000033379 Chorioretinopathy Diseases 0.000 abstract 1
206010010356 Congenital anomaly Diseases 0.000 abstract 1
208000034656 Contusions Diseases 0.000 abstract 1
206010012689 Diabetic retinopathy Diseases 0.000 abstract 1
206010030113 Oedema Diseases 0.000 abstract 1
206010073286 Pathologic myopia Diseases 0.000 abstract 1
206010036105 Polyneuropathy Diseases 0.000 abstract 1
208000005587 Refsum Disease Diseases 0.000 abstract 1
208000002367 Retinal Perforations Diseases 0.000 abstract 1
206010038848 Retinal detachment Diseases 0.000 abstract 1
208000017442 Retinal disease Diseases 0.000 abstract 1
208000007014 Retinitis pigmentosa Diseases 0.000 abstract 1
206010038933 Retinopathy of prematurity Diseases 0.000 abstract 1
208000027073 Stargardt disease Diseases 0.000 abstract 1
208000014769 Usher Syndromes Diseases 0.000 abstract 1
206010058990 Venous occlusion Diseases 0.000 abstract 1
208000036866 Vitreoretinopathy Diseases 0.000 abstract 1
208000027418 Wounds and injury Diseases 0.000 abstract 1
208000021328 arterial occlusion Diseases 0.000 abstract 1
230000015556 catabolic process Effects 0.000 abstract 1
230000009519 contusion Effects 0.000 abstract 1
230000006378 damage Effects 0.000 abstract 1
230000034994 death Effects 0.000 abstract 1
208000001309 degenerative myopia Diseases 0.000 abstract 1
230000004340 degenerative myopia Effects 0.000 abstract 1
238000006731 degradation reaction Methods 0.000 abstract 1
208000035475 disorder Diseases 0.000 abstract 1
210000000981 epithelium Anatomy 0.000 abstract 1
208000008675 hereditary spastic paraplegia Diseases 0.000 abstract 1
230000000302 ischemic effect Effects 0.000 abstract 1
230000003902 lesion Effects 0.000 abstract 1
208000002780 macular degeneration Diseases 0.000 abstract 1
238000004519 manufacturing process Methods 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
230000000149 penetrating effect Effects 0.000 abstract 1
230000002093 peripheral effect Effects 0.000 abstract 1
108091008695 photoreceptors Proteins 0.000 abstract 1
239000000049 pigment Substances 0.000 abstract 1
230000007824 polyneuropathy Effects 0.000 abstract 1
230000006785 proliferative vitreoretinopathy Effects 0.000 abstract 1
210000001525 retina Anatomy 0.000 abstract 1
230000004264 retinal detachment Effects 0.000 abstract 1
230000002207 retinal effect Effects 0.000 abstract 1
210000000242 supportive cell Anatomy 0.000 abstract 1
238000001356 surgical procedure Methods 0.000 abstract 1
208000011580 syndromic disease Diseases 0.000 abstract 1
231100000331 toxic Toxicity 0.000 abstract 1
230000002588 toxic effect Effects 0.000 abstract 1
230000008733 trauma Effects 0.000 abstract 1
230000000472 traumatic effect Effects 0.000 abstract 1
208000019553 vascular disease Diseases 0.000 abstract 1
230000003612 virological effect Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Ophthalmology & Optometry (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biomedical Technology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Peptides Or Proteins (AREA)

AT99912439T 1998-03-12 1999-03-10 Verwendung von fgf-5 polypetiden zur vorbeugung des absterbens retinaler neuronen und behandlung okularer krankheiten ATE226444T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US4138398A	1998-03-12	1998-03-12
US09/240,952 US6331523B1 (en)	1998-03-12	1999-01-29	Method of enhancing the survival of retinal neurons and treating ocular diseases using FGF-5
PCT/US1999/005375 WO1999045952A2 (en)	1998-03-12	1999-03-10	Method of preventing the death of retinal neurons and treating ocular diseases

Publications (1)

Publication Number	Publication Date
ATE226444T1 true ATE226444T1 (de)	2002-11-15

Family

ID=26718088

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT99912439T ATE226444T1 (de)	1998-03-12	1999-03-10	Verwendung von fgf-5 polypetiden zur vorbeugung des absterbens retinaler neuronen und behandlung okularer krankheiten

Country Status (9)

Country	Link
EP (1)	EP1061943B1 (de)
JP (2)	JP3764047B2 (de)
AT (1)	ATE226444T1 (de)
AU (1)	AU754380B2 (de)
CA (1)	CA2322380C (de)
DE (1)	DE69903612T2 (de)
ES (1)	ES2186340T3 (de)
IL (1)	IL138033A0 (de)
WO (1)	WO1999045952A2 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU3755900A (en) *	1999-03-15	2000-10-04	Chiron Corporation	Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
US6943153B1 (en)	1999-03-15	2005-09-13	The Regents Of The University Of California	Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
CA2384696A1 (en) *	1999-10-02	2001-04-12	The Government Of The United States Of America	Fibroblast growth factor-5 (fgf-5) is a tumor associated t-cell antigen
EP1621199B8 (de) *	2003-04-18	2011-01-19	Advanced Medicine Research Institute	Mittel zur behanldung von krankheiten zur aufbringung auf das auge
JP2008064459A (ja) *	2004-12-24	2008-03-21	Univ Kurume	色素上皮由来因子の定量法
GB0700133D0 (en)	2007-01-04	2007-02-14	Humabs Llc	Human cytomegalovirus neutralising antibodies and use thereof
US7947274B2 (en)	2007-01-04	2011-05-24	Humabs, LLC.	Human cytomegalovirus neutralising antibodies and use thereof
DK2352759T3 (en)	2008-07-16	2017-12-18	Inst Res Biomedicine	ANTIBODIES THAT NEUTRALIZE HUMAN CYTOMEGALOVIRUS AND USE THEREOF
TWI698240B (zh)	2012-05-15	2020-07-11	澳大利亞商艾佛蘭屈澳洲私營有限公司	使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd)
WO2015129809A1 (ja) *	2014-02-28	2015-09-03	国立大学法人京都大学	虚血性眼疾患の処置用の医薬組成物
EP3800191B1 (de)	2014-03-17	2025-08-20	Adverum Biotechnologies, Inc.	Zusammensetzungen und verfahren zur verbesserten genexpression in zapfenzellen
US11021519B2 (en)	2015-03-02	2021-06-01	Adverum Biotechnologies, Inc.	Compositions and methods for intravitreal delivery of polynucleotides to retinal cones
GB2545763A (en)	2015-12-23	2017-06-28	Adverum Biotechnologies Inc	Mutant viral capsid libraries and related systems and methods

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1994020125A1 (en) *	1993-03-12	1994-09-15	MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V.	Treatment of motor neuron diseases with fibroblast growth factor-5 (fgf-5)
JPH09510352A (ja) *	1994-03-15	1997-10-21	プリズムファーマシューティカルズ，インコーポレイティド	遺伝子療法及び前部の眼疾患のためのヘパリン結合成長因子
US5629284A (en) *	1995-07-24	1997-05-13	Meiji Milk Products Co., Ltd.	Method for treating retinal diseases
EP2339002A1 (de) *	1996-10-16	2011-06-29	ZymoGenetics, Inc.	Homologe des Fibroblasten-Wachstumsfaktors

1999
- 1999-03-10 AT AT99912439T patent/ATE226444T1/de not_active IP Right Cessation
- 1999-03-10 DE DE69903612T patent/DE69903612T2/de not_active Expired - Lifetime
- 1999-03-10 ES ES99912439T patent/ES2186340T3/es not_active Expired - Lifetime
- 1999-03-10 EP EP99912439A patent/EP1061943B1/de not_active Expired - Lifetime
- 1999-03-10 WO PCT/US1999/005375 patent/WO1999045952A2/en not_active Ceased
- 1999-03-10 JP JP2000535365A patent/JP3764047B2/ja not_active Expired - Lifetime
- 1999-03-10 AU AU30813/99A patent/AU754380B2/en not_active Expired
- 1999-03-10 CA CA002322380A patent/CA2322380C/en not_active Expired - Lifetime
- 1999-03-10 IL IL13803399A patent/IL138033A0/xx active IP Right Grant
2005
- 2005-10-04 JP JP2005290896A patent/JP2006089489A/ja active Pending

Also Published As

Publication number	Publication date
DE69903612T2 (de)	2003-07-10
CA2322380A1 (en)	1999-09-16
DE69903612D1 (de)	2002-11-28
IL138033A0 (en)	2001-10-31
WO1999045952A2 (en)	1999-09-16
AU754380B2 (en)	2002-11-14
JP2002526381A (ja)	2002-08-20
AU3081399A (en)	1999-09-27
ES2186340T3 (es)	2003-05-01
JP2006089489A (ja)	2006-04-06
EP1061943A1 (de)	2000-12-27
WO1999045952A3 (en)	2000-11-23
JP3764047B2 (ja)	2006-04-05
EP1061943B1 (de)	2002-10-23
CA2322380C (en)	2008-10-14

Legal Events

Date	Code	Title	Description
2003-01-15	REZ	Deleted due to withdrawal

Publication	Publication Date	Title
WO2001009327A3 (en)	2001-08-02	Method of preventing the injury or death of retinal cells and treating ocular diseases
ATE226444T1 (de)	2002-11-15	Verwendung von fgf-5 polypetiden zur vorbeugung des absterbens retinaler neuronen und behandlung okularer krankheiten
NO982275D0 (no)	1998-05-19	FremgangsmÕter for behandling av fotoreseptorer under anvendelse av proteinprodukt av gliacellelinjeavledet neurotrof faktor (GDNF)
Valiente-Soriano et al.	2015	BDNF rescues RGCs but not intrinsically photosensitive RGCs in ocular hypertensive albino rat retinas
Pekny et al.	2007	The role of astrocytes and complement system in neural plasticity
Guillery	1986	Neural abnormalities of albinos
Drucker et al.	1959	Pathogenesis of post-traumatic sympathetic dystrophy
Jirsova et al.	1997	Cold jet: a method to obtain pure Schwann cell cultures without the need for cytotoxic, apoptosis-inducing drug treatment
ATE475716T1 (de)	2010-08-15	Zusammenstellungen zur behandlung von neurodegenerativen erkrankungen
AU734801B2 (en)	2001-06-21	Use of nerve growth factor for the storage, culture or treatment of cornea
WO2000053760A3 (en)	2001-01-18	Method of preventing the death of retinal neurons and treating ocular diseases
DE69028877D1 (de)	1996-11-21	Verwendung von Phenylethanolaminen zur Herstellung von Medikamenten gegen Augenleiden
ITRM20100100A1 (it)	2011-09-11	Composizione farmaceutica a base di glicirrizina e polimero eg56 per la preparazione di prodotti ad azione flogolitica.
EP0083261B1 (de)	1988-04-20	Therapeutische Zusammensetzung für die Behandlung von Schwierigkeiten des Anpassungsvermögens des Auges
Copello et al.	2003	Ozone therapy in patients with retinitis pigmentosa
JPS6284025A (ja)	1987-04-17	繊維芽細胞増殖促進作用を有する胎盤由来蛋白加水分解物
Travers et al.	1978	A controlled trial of adenine arabinoside and trifluorothymidine in herpetic keratitis
Møller et al.	1985	Early treatment of granular dystrophy (Groenouw type I)
EP1059931A2 (de)	2000-12-20	Verwendung von cd137 zur förderung der proliferation peripherer monocyten
Srinivas et al.	1989	Haridra (curcuma longa) and its effect on abhisayanda (conjunctivitis)
EP1021461A1 (de)	2000-07-26	Verwendung von blockern neuronaler und lymphozytärer kaliumkanäle zur behandlung von neurologischen krankheiten des immunsystems
Rotman et al.	1994	Two asymptomatic plaques on the chest of a young woman
RU2167667C1 (ru)	2001-05-27	Гомеопатическое средство для рассасывания помутнений роговицы
RU94001223A (ru)	1997-04-10	Глазные капли
Pjister	1968	present in the case described which came from the island of Mors, 25 km from Fur Island.(3 figures, 17 references)-Saul Sugar